Download this clinical summary to read about the benefits of Suliqua in the phase III LixiLan-O study. The study is demonstrating the benefits of Suliqua, a titratable fixed-ratio combination of insulin glargine + lixisenatide vs insulin glargine + lixisenatide monocomponents. This was done in type 2 diabetes patients, inadequately controlled on oral agents.
Rosenstock J, et al. Diabetes Care. 2016; 39: 2026–35.